Surgery for spread pancreatic cancer? small trial halted early
NCT ID NCT06122480
First seen Feb 19, 2026 · Last updated Jun 22, 2026 · Updated 15 times
Summary
This study tested whether surgically removing both the main pancreatic tumor and any limited spread to the liver or lungs could help people with pancreatic cancer live longer. Only 5 people enrolled before the trial was stopped early. Participants first received chemotherapy, then surgery if the cancer remained limited. The goal was to see if this aggressive approach improves survival compared to historical data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
surgery to remove the primary pancreatic tumor and any liver or lung metastases
What this could lead to
If successful, this approach could show that surgery plus chemotherapy improves survival for patients with limited spread of pancreatic cancer.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. Surgery for metastatic pancreatic cancer carries significant risks and may not benefit everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.